Clarifying the Phase 2 efficacy data for PMX-30063 -
Part of the confusion following the release of Phase 2 data on April 23 was the difficulty in comparing the April efficacy data to the December numbers. The December data (92% range) didn't use the new FDA guidelines, while the April data did (70-80% range).
The confusion can be clarified by viewing slide 13, which provides an apples-to-apples comparison to the December data. But unfortunately, the April 23 press release did not include the Slide 13 data, only the lower 70-80% figures from using the new FDA guidelines.
If the April press release had included the Slide 13 data, this is what people would have seen -
Day 3 - (slide 13)
********************
Low Dose - 97.5%
Mid Dose - 91.4%
High Dose - 92.3%
Daptomycin - 91.5%
Day 7 - (slide 13)
********************
Low Dose - 92.5%
Mid Dose - 94.3%
High Dose - 97.4%
Daptomycin - 95.7%
Instead, the only data people saw in the April press release was -
Low Dose - 85.0%
Mid Dose - 71.4%
High Dose - 89.7%
Daptomycin - 74.5%
So it's no wonder that there was/is widespread confusion when trying to compare the April data with the December interim data of 92%. Even seasoned bio stock analysts were probably confused, and may still be.
The April efficacy data (91.4 - 97.5) was actually better than the 92% December data, but the only way to realize that was to see Slide #13 of the presentation slides. The press release didn't show that better data however, only the lower figures, and this has caused considerable confusion over the efficacy of PMX-30063. But as Slide #13 clearly shows, the April data was actually better than the December interim data.
